Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan)
for Prostate Cancer
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a targeted radiopharmaceutical used to treat adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. It is for patients who have not responded to other treatments. Pluvicto, a radioligand therapy, targets the PSMA protein on cancer cells and delivers radiation to kill them, helping to treat advanced prostate cancer.
